Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
Oncotarget|April 21, 2017
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinomaMasayuki Yokoyama, Tetsuhiro Chiba, Yoh Zen, et al.Biochemical and Biophysical Research Communications|March 6, 2021
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsJunjie Ao, Tetsuhiro Chiba, Shuhei Shibata, et al.International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.Plos One|December 21, 2018
Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patientsJunichiro Kumagai, Takashi Taida, Sadahisa Ogasawara, et al.Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.Scientific Reports|November 2, 2021
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinomaYuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, et al.Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.Anticancer Research|February 28, 2023
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 InhibitorsKeita Ogawa, Tetsuhiro Chiba, Masato Nakamura, et al.Journal of Cancer|June 17, 2022
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical ExperienceKeita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.Pageof 8